aTyr Pharma (NASDAQ:ATYR) Announces Earnings Results, Beats Expectations By $0.01 EPS

aTyr Pharma (NASDAQ:ATYR) issued its quarterly earnings results on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, FiscalAI reports. The company had revenue of $189.56 million during the quarter.

aTyr Pharma Price Performance

aTyr Pharma stock opened at $0.51 on Friday. The stock has a market cap of $50.14 million, a price-to-earnings ratio of -0.82 and a beta of 0.54. aTyr Pharma has a 1 year low of $0.40 and a 1 year high of $6.50. The firm has a 50-day moving average of $0.51 and a two-hundred day moving average of $0.70.

Analyst Upgrades and Downgrades

ATYR has been the topic of a number of analyst reports. Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 20th. Weiss Ratings lowered shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $17.00.

Insider Buying and Selling

In related news, Director Paul Schimmel bought 100,000 shares of aTyr Pharma stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average cost of $0.50 per share, with a total value of $50,000.00. Following the completion of the transaction, the director owned 779,143 shares in the company, valued at $389,571.50. The trade was a 14.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.75% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in aTyr Pharma during the 4th quarter worth $62,000. ADAR1 Capital Management LLC grew its position in shares of aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after buying an additional 13,385 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of aTyr Pharma during the 4th quarter worth $603,000. Deutsche Bank AG increased its stake in shares of aTyr Pharma by 3,779.5% during the fourth quarter. Deutsche Bank AG now owns 120,341 shares of the company’s stock valued at $94,000 after buying an additional 117,239 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of aTyr Pharma by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after buying an additional 105,514 shares during the period. Institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.